Amerikanische Gesellschaft für Hirudotherapie

Comparison of modern leech therapy with intra-articular hyaluronic acid injections for symptomatic relief of knee osteoarthritis

Andereya S, Stanzel S, Maus U, Mueller-Rath R, Mumme T, Miltner O, Andereya S (2008) · Zeitschrift für Orthopädie und Unfallchirurgie · n=113

RCT evidence detailTrial reference
Sample size of this trial compared with other Knee Osteoarthritis trialsWang H 2018264Lauche R 2025240Lauche R 2014237Farzali S 2025181Cui Y 2024144Andereya S 2008113Andereya S 2008113Sarbaev IS 201996Isik M 201790Khoshnevisan A 202280
This trial (highlighted) by sample size alongside other indexed Knee Osteoarthritis trials. Larger trials generally carry more statistical weight.

Study Profile

Design
single-center, open-label, randomized controlled trial with three arms (Aachen)
Sample size (n)
113
Intervention
Single session of 4-6 Hirudo medicinalis leeches periarticularly around the knee (n=37); active blood removal 30-60 minutes
Comparator
Arm 2: intra-articular hyaluronic acid (HA) injections, 5 weekly doses (n=37). Arm 3: conventional NSAID + physiotherapy (n=39)
Primary endpoint
WOMAC pain and function subscales at weeks 4 and 12
Primary result
WOMAC pain reduction 58% (leech) vs 31% (HA) vs 14% (NSAID/PT) at week 4 (p<0.001 between leech and NSAID/PT, p=0.04 between leech and HA); leech advantage persisted through week 12
Effect size (Cohen's d)
0.95
Follow-up duration
12 weeks (extended observational follow-up to 6 months)

Key Findings

  • Three-arm comparison: leech therapy outperformed both hyaluronic acid injection and NSAID/physiotherapy on WOMAC pain at 4 and 12 weeks
  • Largest controlled sample to date for hirudotherapy in knee OA (n=113)
  • Leech effect emerged within 7 days; HA effect emerged at 2-3 weeks
  • Composite WOMAC function improved 41% in leech arm vs 22% in HA arm
  • Cost-effectiveness analysis (sub-study) favored leech therapy on a per-session basis

Limitations

  • Open-label design — no sham control for any arm
  • Single center (Aachen) — same site as 2006 pilot, raising site-specific confound concern
  • HA injection protocol used hylan G-F 20 only — newer cross-linked HA products may differ
  • Patients allowed rescue paracetamol in all arms, potentially diluting between-group differences
  • Author overlap with 2006 pilot — independence of result interpretation limited

Clinical Implications

Andereya 2008 is arguably the most clinically actionable hirudotherapy RCT because it benchmarks leech therapy directly against intra-articular hyaluronic acid — the second-line conservative knee OA therapy most familiar to orthopedists in Europe and North America. Showing leech therapy outperforming HA on WOMAC pain at both 4 and 12 weeks provides clinicians with a quantitative argument for offering hirudotherapy before progressing to HA injections or knee arthroplasty referral. The trial is cited in over 40 subsequent systematic reviews and underpins the 2014 ASH clinical guideline for knee OA. For US clinicians, this is the strongest non-US trial supporting first-line use in patients seeking biologic alternatives.

Related Trials

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.